Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Bone Disease and Chronic Kidney Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FGF23 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FGF23 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed to preserve native O-glycosylation essential for preventing proteolytic cleavage. |
View FGF23 Products |
| Gene Delivery | FGF23 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and in vitro expression validation. |
View FGF23 Products |
| Benchmark Ab | Anti-FGF23 (Sequence of Burosumab) Recombinant humanized IgG1 monoclonal antibody positive control. |
View FGF23 Products |
| Validator | FGF23 siRNA Set Target-specific knockdown verification in osteocyte/osteoblast cell models. |
View FGF23 Products |
| Related Target A | Klotho (alpha-Klotho) Essential co-receptor for FGF23 signaling; critical for establishing functional FGFR/Klotho binding assays. |
View Klotho Products |
| Related Target B | FGFR1 Primary signaling receptor partner for FGF23 in the kidney and parathyroid gland. |
View FGFR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing Intact FGF23 from Cleaved Fragments | Sequence-verified intact FGF23 (R176/179 mutant available to prevent furin cleavage) with >95% purity. |
| Reconstitution of Co-receptor Complex | High-purity recombinant alpha-Klotho and FGFR1 proteins available to build robust ternary complex binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Burosumab biosimilar) included for functional assay calibration. |
| False Positives | Validated siRNA included for target-specificity checks in cell-based assays. |
Live FGF23 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of FGF23 is a validated paradigm, highlighted by the clinical approval of Burosumab (Crysvita) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). The race for FGF23 therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation modalities including bispecific antibodies, small molecule FGFR/Klotho modulators, and peptide mimetics. As first-generation therapies reach the clinic, the next wave of R&D is targeting chronic kidney disease (CKD)-associated hyperphosphatemia and left ventricular hypertrophy, where managing the FGF23-Klotho axis is crucial for reducing cardiovascular mortality.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Kyowa Kirin, Ultragenyx | XLH, Tumor-Induced Osteomalacia (TIO) | Epitope mapping & ligand blocking assays (Need glycosylation-verified intact FGF23) |
| Bispecific / Fusion Protein | Amgen, Chugai | CKD-MBD, Osteoporosis | Heterodimer validation & ternary complex (FGF23-FGFR-Klotho) assembly assays |
| Small Molecule / Peptide | AstraZeneca, Various Academics | Cardiovascular disease in CKD | Selectivity assays against other FGF family members (Need FGF21, FGF19 homolog panels) |